Kornimate/medical-research-clean huggingface dataset:
panda-regional feasibility study of a smartphone pain management application

Conditions: Postoperative Pain; Anesthesia, Conduction

Summary: despite the numerous benefits of peripheral nerve blocks (pnbs) over general anesthesia (ga) in a variety of surgical procedures, pnbs can be associated with increased post-operative pain if pain medications are not taken correctly (titrated). unfortunately, this is a common occurrence as patients often have difficulty titrating medications in the absence of direct medical care. panda, a smartphone-based postoperative pain management tool, is designed to address this issue by helping patients manage their pain medications. the purpose of this study is to demonstrate the feasibility of this application in patients who are discharged after receiving pnbs. the goal is to identify areas of improvement for the application itself. it is hypothesize that panda will be successful in supporting patients' postoperative pain management.

as above

Eligibility criteria:
inclusion criteria: * undergoing ambulatory surgical procedures that require peripheral nerve blocks for which there is an anticipated post-surgical pain model * planned post-discharge analgesic medications including non-steroidal anti-inflammatory drugs, acetaminophen and/or opioids for at least 2 days * asa i-iii * written informed consent * have a smartphone device at their disposal exclusion criteria: * inability or refusal to provide informed consent * presence of significant cognitive impairment, visual impairments, neurological injury, or psychomotor dysfunction that impairs ability to use the app * inability to follow study instructions and complete questionnaires in english
activator and type ii diabetics

Conditions: Type II Diabetes

Summary: the purpose of this study (15-subject prospective case series) is to examine the effects of the activator methods technique on decreasing a1c levels in patients with type ii diabetes mellitus (aka adult-onset diabetes).


Eligibility criteria:
inclusion criteria: * subjects will be eligible to participate in the study if they are between the ages of 30-60 and are clinically diagnosed with type ii diabetes by their primary care providers or endocrinologists (diagnosis usually based on fpg \> 126 mg/dl on two occasions). * participants must have been diagnosed for at least one year and currently be under medical supervision for the disease. * they must also have an a1c measurement above 7%, which indicates less than optimal management of the disease. exclusion criteria: * the study will exclude pregnant women; * those with co-morbidities affecting life expectancy (e.g. malignancy, cvd); uncontrolled hypertension (\> 150/100 mmhg); * serious trauma (e.g. mva) within the previous 12 months; * diagnosed bleeding/clotting disorders; those currently under chiropractic care or having contraindications to activator care (e.g. vertebral fracture, infection, active inflammatory arthritis, severe osteoporosis). the presence of these exclusions will be determined during the history and exam procedures. all female subjects will be asked to take precautions during their participation in the study to avoid becoming pregnant.

Keywords: diabetes
effects of a 12-week respiratory muscles training program in persons with relapsing- remitting multiple sclerosis

Conditions: Relapsing-remitting Multiple Sclerosis

Summary: multiple sclerosis (ms) is the most common inflammatory demyelinating chronic disease of the central nervous system and the second leading cause of disability in young adults. motor deficits also involve respiratory muscles. this involvement is present from early stages of disease and is frequently dismissed by professionals until advanced stages of disease. the effect of a training program of respiratory muscles is not sufficiently studied. the aim of this research is to assess the clinical and functional response of a 12-week respiratory muscles training program (rmtp) for persons with relapsing-remitting multiple sclerosis (rrms). this study is consisted with two sub research: firstly, a single-blind randomized clinical trial will be carried out in 40 persons with rrms. participants either will be received (n = 20) peripheric resistive muscle training program which will be supplemented by a 12-week respiratory muscles training program (rmtp) with orygen dual® device for 50 minutes, twice a week during three months or (n = 20) they will be received peripheric resistive muscle training program and health education program. main outcomes will be strength of the respiratory muscles assessed by maximal inspiratory and expiratory pressure measurements (mip and mep). the secondary outcomes will be assessed the quality of life (msqol-54), walking speed (t25-fw, msws-12 and hauser ambulatory index), fatigue (mfis), endurance of the respiratory muscles (10rm) manoeuvre and peripherical muscle strength (multiple-sit-to-stand test and handgrip strength). secondly, the qualitative research where researchers will interview participants about their interest in carrying out the intervention (difficulties and advantages) and identify themes of interest about changes in quality of life.


Eligibility criteria:
inclusion criteria: * males and females older 18 years of age with diagnosis relapsing-remitting multiple sclerosis according to revised mcdonald criteria 2005. * have mild or moderate impairment of gait according to hauser ambulatory index. the score 1 and 5 will be included (both values inclusive). * subjects who have read, understood, signed and dated the informed consent form. exclusion criteria: * disability caused by other diseases * clinically relevant cognitive or linguistic disorders which are unable to fill in the questionnaires by him/herself * subjects used medication with corticosteroids within the last month (or 30 days) prior to study day 1. * have a recent outbreak (last month) not stabilized prior to inclusion in the study

Keywords: multiple sclerosis respiratory muscle strength maximal inspiratory pressure (mip) maximal expiratory pressure (mep) respiratory muscle endurance quality of life qualitative research
transversus abdominis plane block with or without buprenorphine after inguinal hernia surgery

Conditions: Inguinal Hernia; Pain, Postoperative

Summary: buprenorphine intravenous, sublingual, and transdermal patches have been researched for their antihyperalgesic effects, although peripherally mediated effects have not been examined in egypt surprisingly

this prospective, randomized, double-blind controlled trial involved 88 patients who were scheduled for inguinal hernia surgery followed by a tap block. patients were allocated into group b (n= 44) received 20 ml of 0.25% ropivacaine for tap block; group br (n= 44) received 20 ml of 0.25% ropivacaine containing 300 μg of buprenorphine for tap block. the primary outcome of the study was the analgesic and antihyperalgesic effect of buprenorphine compared to the control group. the duration of analgesia, analgesic consumption, postoperative pain scores at rest and sitting up to 48 hrs, and effect on wound hyperalgesia at 24 and 48 hrs were evaluated. secondary outcomes of the study include incidence of side effects and tap block-related complications were recorded. effect of buprenorphine on patients with predicted high pain scores and incidence of persistent postoperative pain were also determined. a transversus abdominis plane (tap) block provides analgesia of the anterior and lateral abdominal wall below the umbilicus by blocking the t6-l1 segmental nerves as they lie within the fascial plane between the transversus abdominis and internal oblique muscles: bilateral block for midline abdominal incision. it was first described in 2001 by rafi as a traditional blind landmark technique using the lumbar triangle of petit. local anesthetic is then injected between the internal oblique and transverse abdominis muscles just deep the fascial plane, the plane through which the sensory nerves pass

Eligibility criteria:
inclusion criteria: 1. patients with inguinal hernia 2. medically free exclusion criteria: 1. participants with a history of heart, renal and liver cell failure. 2. allergic reaction to studied drugs, and history of epilepsy, 3. hydrodynamic instability, 4. chronic pain. 5. mental illness.
preoperative bevacizumab and trastuzumab with abi-007 and carboplatin in her2+ breast cancer

Conditions: Breast Cancer

Summary: this trial combines trastuzumab and bevacizumab monoclonal antibodies, with abi-007 and carboplatin, as neoadjuvant therapy in previously untreated locally advanced breast cancers demonstrating her2 gene amplification. it is hoped that this novel combination will result in increased pathologic response rates that will translate into long term outcome improvements in her2 positive patients with locally advanced breast cancer.

all eligible patients will receive induction chemotherapy prior to consideration of primary surgical intervention. if surgical intervention is deemed not to be in the best interest of the patient, patient will go off study at the time of evaluation for surgery. upon completion of chemotherapy and surgery, all er + and/or pr + patients will be placed on tamoxifen 20 mg/qd or an aromatase inhibitor. induction preoperative therapy: * bevacizumab * trastuzumab * abi-007 * carboplatin postoperative adjuvant therapy: * bevacizumab * trastuzumab

Eligibility criteria:
inclusion criteria: * female patients with histologically confirmed adenocarcinoma of the breast or inflammatory breast cancer * clinical stage t 1-4, n 0-3, m0 * fish+ her2 gene amplified breast cancer * 18 years or older * normal cardiac function * performance status 0-2 * cannot have received any prior chemotherapy for this disease or cannot have received chemotherapy for any other cancer in the past 5 years. * previous diagnosis of noninvasive breast cancer is ok. * must have adequate bone marrow, renal and liver function. * pregnant or lactating females not allowed. * preexisting peripheral neuropathy must be equal to or less than grade 1 * must have archived tumor tissue for tissue testing. exclusion criteria: you cannot be in this study if you any of the following: * history of cardiac disease, with new york heart association class ii or greater with congestive heart failure * any heart attack, stroke or tias within the last 6 months or serious arrhythmias needing medication; no bleeding diathesis or coagulopathy. * no prior investigational drug within the last 30 days * no prior trastuzumab or bevacizumab therapy there are additional inclusion/exclusion criteria. the study center will determine if you meet all of the criteria. if you do not qualify for the trial, study personnel will explain the reasons.

Keywords: breast cancer
affixing polypropylene mesh using barbed suture (quill™ srs) during laparoscopic sacrocolpopexy randomized controlled trial (quill lsc)

Conditions: Prolapse

Summary: 1.0 study objective 1.1 primary objective - to compare two methods of polypropylene mesh attachment during laparoscopic sacrocolpopexy (lsc): running technique using self-anchoring 1 barbed delayed absorbable suture (quill™ srs, angiotech pharmaceuticals, inc. vancouver, canada) versus interrupted technique using 0 non-barbed delayed absorbable suture (pds ii™, ethicon, somerville, nj, usa). 1.2 secondary objective - to compare laparoscopic sacrocolpopexy anatomic failure rates at 6 months post-operative follow-up using self-anchoring 1 barbed delayed absorbable suture (quill™ srs, angiotech pharmaceuticals, inc. vancouver, canada) versus 0 non-barbed delayed absorbable suture (pds ii™, ethicon, somerville, nj, usa). the investigators will also assess mesh erosion rates, costs, and surgeon satisfaction rates. 2.0 hypothesis 2.1 primary: 2.1.a. attachment of mesh using the running technique with self-anchoring 1 barbed delayed absorbable suture (quill™ srs, angiotech pharmaceuticals, inc. vancouver, canada) will be faster than the standard fixation interrupted technique using 0 non-barbed delayed absorbable suture (pds ii™, ethicon, somerville, nj, usa). 2.2 secondary: 2.2.a. attachment of mesh using the running technique with self-anchoring 1 barbed delayed absorbable suture (quill™ srs, angiotech pharmaceuticals, inc. vancouver, canada) will be less costly than the standard fixation interrupted technique using 0 non-barbed delayed absorbable suture (pds ii™, ethicon, somerville, nj, usa). 2.2.b. failure rates and mesh erosion rates for each technique will be equally low. 2.2.c. surgeons will prefer the barbed running technique over the interrupted technique based on subjective surgeon satisfaction questionnaires.


Eligibility criteria:
inclusion criteria * \>18 years old * undergoing lsc with or without other procedures for pelvic organ prolapse or incontinence * willing to return for follow-up visits * written informed consent obtained from each subject * must be having a robotic assisted laparoscopic sacrocolpopexy exclusion criteria: * decline to participate * pregnant or contemplating future pregnancy * unable to participate in the informed consent process

Keywords: sutures pelvic organ prolapse sacrocolpopexy laparoscopy
natalizumab subcutaneous immunogenicity and safety study

Conditions: Relapsing Multiple Sclerosis

Summary: the primary objective of this study is to evaluate the immunogenicity of natalizumab (bg00002) 300 mg subcutaneous (sc) administered to participants with relapsing multiple sclerosis (rms). the secondary objectives of the study are to evaluate the safety of natalizumab sc injections and to evaluate the efficacy of natalizumab sc injections on relapses and on new magnetic resonance imaging (mri) lesions.


Eligibility criteria:
key inclusion criteria: * must have documented diagnosis of rms at screening. * must fall within the therapeutic indications stated in the locally approved label for natalizumab. * must have an edss score from 0 to 6.5, inclusive. key exclusion criteria: * any prior use of natalizumab. * positive for anti-natalizumab antibodies at screening. * treatment with immunomodulatory injections (including ifn-β and glatiramer acetate) within 2 weeks prior to screening. note: other protocol defined inclusion/exclusion criteria may apply
asymptomatic bacteriuria in pregnancy in low- and middle-income countries

Conditions: Preterm Birth; Small for Gestational Age (SGA); Stillbirth; Bacteriuria (asymptomatic) in Pregnancy

Summary: this study, asymptomatic bacteriuria in pregnancy in low- and middle-income countries (able), is designed as a 2-arm randomized controlled trial (rct) focused on pregnant individuals and newborn infants. a positive outcome of this study will contribute to global progress toward who sustainable development goal target 3.2 \[end preventable deaths of newborns and children under 5 years of age\] by examining the potential impact of this practice to reduce the incidence of svn/sb and the lifelong health consequences associated with svns. in addition, the study will further explore the role and potential benefits of antibiotic treatment of ab in the pregnant individual. in total, 1,134 eligible participants, or approximately 162 per research site, will be randomized in the trial by the research teams in each of the seven international sites that, together with their united states of america (us) partners, participate in the eunice kennedy shriver national institute of child health and human development's (nichd's) global network for women's and children's health research (gn).


Eligibility criteria:
inclusion criteria: individuals who meet the following criteria are eligible for randomization: * enrolled in gn mnhr * established pregnancy ≥12 and ≤20 weeks ga by last menstrual period and/or clinical assessment and/or ultrasonography * age: 18 years (or lower limit age eligible\*) to 49 years \* some sites will be able to include individuals giving birth regardless of age if they are considered an adult or an emancipated minor. however, other sites will require individuals to be at least 18 years of age. the investigators will adhere to local regulations. * expressed understanding of study procedures and willingness to complete screening, randomization, study drug administration and follow-up * able to provide informed consent * presence of a single bacterial isolate (\>105 colony forming unit (cfu)/ml) in urine at enrollment * intent to remain in study area for at least 42 days pp exclusion criteria: individuals who meet any of the following criteria are not eligible for randomization: * gestational age \ 20 weeks * received treatment with any antibiotic within 14 days before screening visit * current symptoms of uti * history of allergy to nitrofurantoin * pregnancy loss / miscarriage prior to randomization * currently taking magnesium-containing antacid * any illness / condition (e.g., anemia, diabetes, renal disease, pulmonary disease) requiring immediate medical care per site pi assessment * enrollment in another trial that per the study mop will impact this trial

Keywords: asymptomatic bacteriuria small vulnerable newborn preterm birth small for gestational agea still birth svn/sb oral nitrofurantoin monohydrate/macrocrystals global network bangladesh india pakistan democratic republic of congo zambia guatemala
a study with a initial treatment period followed by a randomized-withdrawal period to evaluate the efficacy and safety of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis

Conditions: Chronic Plaque Psoriasis; Moderate to Severe Chronic Plaque Psoriasis; Psoriatic Arthritis

Summary: phase 3 study to compare the efficacy of bimekizumab versus placebo in the treatment of subjects with moderate to severe chronic plaque psoriasis.


Eligibility criteria:
inclusion criteria: * must be at least 18 years of age * chronic plaque psoriasis (pso) for at least 6 months prior to the screening visit * psoriasis area severity index (pasi) \>=12 and body surface area (bsa) affected by pso \>=10% and investigator's global assessment (iga) score \>=3 on a 5-point scale * subject is a candidate for systemic pso therapy and/or phototherapy * female subject of child bearing potential must be willing to use highly effective method of contraception exclusion criteria: * subject has an active infection (except common cold), a recent serious infection, or a history of opportunistic, recurrent, or chronic infections * subject has concurrent acute or chronic viral hepatitis b or c or human immunodeficiency virus (hiv) infection * subject has known tuberculosis (tb) infection, is at high risk of acquiring tb infection, or has current or history of nontuberculous mycobacterium (ntmb) infection * subject has any other condition, including medical or psychiatric, which, in the investigator's judgment, would make the subject unsuitable for inclusion in the study * presence of active suicidal ideation or positive suicide behavior * presence of moderately severe major depression or severe major depression * subject has any active malignancy or history of malignancy within 5 years prior to the screening visit except treated and considered cured cutaneous squamous or basal cell carcinoma, or in situ cervical cancer

Keywords: bimekizumab pso psoriasis
evaluation of acacia catechu and low-level laser in the treatmentof stage ii periodontitis

Conditions: Chronic Periodontitis

Summary: evaluation of acacia catechu and low-level laser in the treatment of stage 2 periodontitis.

* assess the effectiveness of a. catechu gel (local delivery) adjunctive to non surgical therapy in the treatment of stage chronic periodontitis. clinical and biochemical evaluation. * compare the effectiveness of a. catechu gel (local delivery) and low-level laser adjunctive to non-surgical therapy in the treatment of stage chronic periodontitis. clinical and biochemical evaluation.

Eligibility criteria:
inclusion criteria: 1. motivated patient with good oral hygiene. 2. age ranges from (30-50) years. 3. free from any systemic disease according to the cornell medical index (16). exclusion criteria: 1. patients who received periodontal treatment over the 12 months preceding the study. 2. patients who consumed antibiotics or anti-inflammatory drugs within the last 3 months. 3. previous or current radiation or immunosuppressive therapies. 4. pregnant \& lactating women. 5. patient with orthodontic appliances. or having partial dentures. 6. patient with parafunctional habits.

Keywords: chronic periodontitis herbal medicine low level laser therapy adjunctive therapy acacia catechu
study of gw679769 in major depressive disorder

Conditions: Depressive Disorder, Major; Major Depressive Disorder (MDD)

Summary: this is a placebo-controlled, fixed dose study that will evaluate the efficacy and safety of gw679769 in subjects with major depressive disorder.


Eligibility criteria:
inclusion criteria: * subjects must have the ability to comprehend the key components of the consent form. * subject must have met dsm-iv-tr (diagnostic and statistical manual of mental disorders, fourth edition, text revision) criteria for current mde (major depressive episode) for at least 8 weeks prior to the screening visit. * if female, subjects must be practicing an acceptable method of birth control. * subjects must have rating scores as outlined. exclusion criteria: * subjects whose symptoms of the mde are better accounted for by another diagnosis. * subjects with a history of schizophrenia, schizoaffective disorders or bipolar disorder. * subjects have a positive urine test for illicit drug use and/or a history of substance abuse or alcohol dependence within the past 12 months. * subjects with an unstable medical disorder. * if female, pregnant or lactating. * subjects who have received ect (electroconvulsive therapy) or tms (transcranial magnetic stimulation) within the 6 months preceding screening or who have ever been homicidal.

Keywords: major depressive disorder major depression mood disorders major depressive episode
cafe comparison of atypicals in first episode of psychosis

Conditions: Schizophrenia; Psychotic Disorders; Mental Health; Mental Disorders

Summary: the purpose of this study is to compare the effectiveness, tolerability, and efficacy of the currently available atypical antipsychotic drugs olanzapine (2.5-20 mg/day), quetiapine (100-800 mg/day) and risperidone (0.5-4 mg/day) in patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder who are experiencing their first psychotic episode.


Eligibility criteria:
inclusion criteria: * patients must meet criteria for schizophreniform disorder, schizophrenia, or schizoaffective disorder with psychotic symptoms lasting 1-60 months * psychotic symptoms must have persisted at least one month, and not more thn 5 years (60 months) * patients must have no previous history of drug treatment (greater than a total of 16 weeks) with antipsychotics exclusion criteria: * patients with history of psychotic disorder with recovery period of at least 3 months * female patients who are pregnant or nursing * patients with a known history of mental retardation